Form 4: Annovis Bio Director Boosts Stake with $159K Stock Purchase

Annovis Bio, Inc. Director Michael B. Hoffman acquired 39,200 shares of common stock for approximately $159,875 on November 24, 2025.

Summary

• Michael B. Hoffman, a Director of Annovis Bio, Inc., purchased a total of 39,200 shares of the company's common stock.
• The transactions occurred on November 24, 2025, with purchase prices ranging from $3.85 to $4.15 per share.
• The total value of the acquired shares amounts to approximately $159,875.07.
• Following these transactions, Mr. Hoffman directly holds 2,519,739 shares of common stock.
• Additionally, Mr. Hoffman indirectly holds 223,357 shares through The 2018 Jane and Michael Hoffman Descendants Trust, over which he has voting and investment power.

Sentiment

Score: 7

Explanation: Insider buying by a director generally indicates confidence in the company's future prospects, which is a positive signal for investors regarding the company's internal outlook.

Positives

• Director Michael B. Hoffman increased his direct beneficial ownership by 39,200 shares, signaling confidence in the company's future prospects.
• The purchases were made at market prices, indicating a belief in the current valuation and potential for appreciation.
• The significant increase in insider ownership aligns management's interests more closely with those of shareholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Increased insider ownership may be viewed positively by shareholders as it aligns management interests with shareholder interests, potentially boosting investor confidence.

Key Dates

Recommendation

The director's significant purchase of company stock signals confidence in Annovis Bio's future, which is a positive indicator for current shareholders. However, a single insider transaction, without further fundamental analysis or broader market context, typically supports a 'hold' recommendation rather than an immediate 'buy' or 'sell'.

Keywords

Annovis Bio, ANVS, Insider Buying, Stock Purchase, Director, Michael B. Hoffman, SEC Form 4, Biotechnology, Pharmaceuticals